Top 10 Companies in the Southeast Asia Animal Antimicrobials Market (2026): Leaders Shaping Regional Veterinary Supply Chains

MARKET INSIGHTS

Southeast Asia Animal Antimicrobials Market – View in Detailed Research Report

The Southeast Asia Animal Antimicrobials market size was valued at USD 0.92 billion in 2024. The market is projected to grow from USD 0.98 billion in 2025 to USD 1.45 billion by 2032, exhibiting a CAGR of 5.7 % during the forecast period. The base year for the analysis is 2025, with an estimated 2026 figure of USD 1.02 billion and a full‑forecast 2034 value of USD 1.55 billion.

Animal antimicrobials are pharmaceutical agents used to prevent, control, or treat microbial infections in animals. These substances, primarily antibiotics but also including antifungals and antiprotozoals, target bacteria, fungi, and other pathogens in livestock and companion animals. They are essential for maintaining animal health, supporting productivity in food‑producing sectors, and ensuring welfare in pets. Common types encompass tetracyclines, beta‑lactams, macrolides, and sulfonamides, delivered through forms such as premixes, oral powders, solutions, injections, and others.

The market is witnessing steady growth fueled by the region’s expanding livestock industry, driven by population growth and rising demand for animal‑derived proteins. However, increasing concerns over antimicrobial resistance (AMR) and stricter regulations in countries like Thailand and Vietnam are prompting shifts toward judicious use and alternatives. Furthermore, growing pet ownership in urban areas boosts demand for companion animal treatments. Key initiatives include ASEAN‑wide efforts to monitor AMR, with companies like Zoetis Inc., Boehringer Ingelheim, and Elanco Animal Health leading innovations in sustainable solutions. For instance, in March 2024, Boehringer Ingelheim expanded its veterinary portfolio in Indonesia with new low‑resistance antibiotic formulations.

Top 10 Companies in the Southeast Asia Animal Antimicrobials Market

1. Zoetis

   Headquarters: Parsippany, New Jersey, USA
   Key Offering: Premixed feed additives, oral powders, injectable antibiotics for poultry and swine.

   Zoetis has leveraged a global research network to develop low‑resistance antibiotic blends that meet emerging residue standards in Thailand and Vietnam. The company’s focus on precision dosing tools positions it as a preferred supplier for large integrated feed mills.

   Sustainability Initiatives:

   • Investing in vaccine‑based disease control to reduce antibiotic reliance.
   • Collaborating with ASEAN veterinary authorities to refine residue monitoring protocols.
   • Targeting a 15 % reduction in antibiotic usage across its product portfolio by 2030.

2. Elanco Animal Health

   Headquarters: Lexington, Kentucky, USA
   Key Offering: Broad spectrum antibiotics, anti‑parasite agents, and immunomodulators for swine and poultry.

   Elanco’s portfolio includes a range of low‑resistance beta‑lactams that satisfy the stringent import controls in Indonesia. The firm’s rapid response to regulatory changes has cemented its position in the Indonesian market.

   Sustainability Initiatives:

   • Developing phytogenic feed additives to complement antibiotic therapy.
   • Supporting local feed‑mill partnerships to promote stewardship education.
   • Rolling out a digital dosing platform to reduce over‑use.

3. Bayer Animal Health

   Headquarters: Leverkusen, Germany
   Key Offering: Premixed tetracyclines, macrolides, and sulfonamides for poultry and aquaculture.

   Bayer’s active involvement in ASEAN AMR monitoring has enabled the company to tailor its product formulations to regional pathogen profiles, thereby enhancing efficacy and market acceptance.

   Sustainability Initiatives:

   • Investing in vaccine research for common poultry diseases.
   • Implementing closed‑loop supply chain traceability.
   • Promoting responsible antibiotic use through farmer training programs.

4. Merck Animal Health

   Headquarters: Kenilworth, New Jersey, USA
   Key Offering: Injectable beta‑lactams and anti‑protozoal agents for swine and cattle.

   Merck’s focus on precision dosing and real‑time monitoring aligns with the ASEAN push for data‑driven stewardship. The company’s presence in Vietnam’s feed‑lot sector has grown steadily over the past three years.

   Sustainability Initiatives:

   • Launching a phage‑based therapy line for aquaculture pathogens.
   • Supporting local research on antimicrobial resistance genetics.
   • Engaging in joint ventures to expand low‑resistance antibiotic production.

5. Boehringer Ingelheim

   Headquarters: Ingelheim am Rhein, Germany
   Key Offering: Low‑resistance macrolides and beta‑lactams for poultry and swine.

   In March 2024, Boehringer Ingelheim introduced a new low‑resistance antibiotic formulation in Indonesia, positioning itself as a leader in compliance‑friendly products.

   Sustainability Initiatives:

   • Investing in next‑generation antimicrobial stewardship platforms.
   • Collaborating with local universities to develop novel anti‑microbial compounds.
   • Targeting a 20 % reduction in high‑resistance drug use by 2030.

6. Vetoquinol

   Headquarters: Besançon, France
   Key Offering: Oral powders and injectable antibiotics for companion animals.

   Vetoquinol’s focus on pet‑care segments aligns with rising urban pet ownership in Thailand and Vietnam. The company’s low‑resistance formulations are well‑received in markets with strict residue limits.

   Sustainability Initiatives:

   • Developing probiotic supplements to reduce antibiotic dependence.
   • Partnering with veterinary clinics for stewardship education.
   • Expanding a digital health passport for pet medication tracking.

7. PT Interchemie

   Headquarters: Jakarta, Indonesia
   Key Offering: Targeted oral powders and injection blends for intensively farmed species.

   PT Interchemie’s localized production allows rapid adaptation to country‑specific disease profiles, giving it a competitive edge in Indonesia’s fragmented market.

   Sustainability Initiatives:

   • Integrating precision feeding sensors with antimicrobial delivery.
   • Developing low‑resistance antibiotic lines in partnership with local universities.
   • Implementing a cold‑chain monitoring system to preserve product potency.

8. Huvepharma

   Headquarters: Sofia, Bulgaria
   Key Offering: Oral solutions and injections for poultry and swine.

   Huvepharma’s focus on cost‑effective, low‑resistance formulations has attracted attention from regional distributors seeking to meet tightening residue regulations.

   Sustainability Initiatives:

   • Investing in vaccine research for poultry diseases.
   • Collaborating with ASEAN veterinary bodies to standardise antimicrobial usage guidelines.
   • Expanding a digital platform for real‑time usage tracking.

9. Bayer

   Headquarters: Leverkusen, Germany
   Key Offering: Premixed tetracyclines and macrolides for poultry and aquaculture.

   Bayer’s extensive research pipeline has enabled it to introduce low‑resistance formulations that align with the ASEAN AMR monitoring framework.

   Sustainability Initiatives:

   • Developing vaccine‑based disease prevention programs.
   • Implementing blockchain traceability for feed‑premix supply chains.
   • Reducing antibiotic usage by 10 % across its product lines by 2030.

10. Boehringer Ingelheim

    Headquarters: Ingelheim am Rhein, Germany
    Key Offering: Low‑resistance macrolides for poultry and swine.

    Re‑launching a new line of low‑resistance antibiotics in Indonesia has reinforced Boehringer’s leadership in compliance‑friendly products.

    Sustainability Initiatives:

    • Investing in next‑generation antimicrobial stewardship platforms.
    • Collaborating with local universities to develop novel anti‑microbial compounds.
    • Targeting a 20 % reduction in high‑resistance drug use by 2030.

Southeast Asia Animal Antimicrobials Market – View in Detailed Research Report

Southeast Asia Animal Antimicrobials Market – View in Detailed Research Report

Outlook

The Southeast Asian region is poised to see a steady uptick in antimicrobial usage as livestock production expands. The regulatory landscape, marked by harmonised approval pathways and stricter residue limits, is likely to accelerate the adoption of low‑resistance formulations and precision dosing solutions. Companies that embed digital tools and alternative therapies into their portfolios are positioned to capture premium market share.

Future Trends

• Growth of precision veterinary solutions that enable pathogen‑specific therapy.
• Increasing demand for organic and antibiotic‑free animal products, spurring investment in bacteriophage and immunomodulator therapies.
• Enhanced traceability through blockchain and digital health passports, providing real‑time visibility for regulators and consumers.
• Collaboration between multinational manufacturers and local research institutions to accelerate low‑resistance drug development.
• Adoption of closed‑loop feeding systems that reduce blanket antibiotic use and improve farm economics.